Skip to content

Halozyme Therapeutics

US · HALO #1276 by market cap Listed 1970
91.35 -1.69 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 92.73 -0.33%
After-hours 91.35 0.00%
Overnight 92.97 -0.08%
131.1866.2891.352026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on HALO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +9.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 22.8x Better than 34%
Forward P/E 9.3x Better than 84%
Price / Sales 5.8x Better than 19%
P/E vs own 5-yr range 65th pctl Better than 44%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 28.4% Better than 89%
Net income CAGR (3Y) 16.2% Better than 68%
Free cash flow CAGR (3Y) 14.9% Better than 59%
Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 83.6% Better than 93%
Operating margin 57.5% Better than 99%
Net margin 22.7% Better than 83%
Return on equity 153.6% Better than 98%
Return on invested capital 16.2% Better than 84%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -15.5% Better than 39%
6-month return 33.7% Better than 91%
12-month return (ex latest month) 78.6% Better than 92%
Distance below 52-week high 31.8% Better than 40%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.7x Better than 84%
Debt to assets 84.8% Better than 3%
Interest coverage 26.8x Better than 85%
Free cash flow / net income 112.6% Better than 47%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 80.0% Better than 58%
Upside to average target 37.5% Better than 57%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.90%
1M -26.55%
3M -13.92%
6M +32.43%
YTD +35.74%
1Y +32.45%
3Y +128.32%
5Y +157.11%

Key statistics

Price & volume

Prev close
93.04
Open
93.64
Day range
90.79 - 93.64
Avg price
92.07
Volume
1.50M
Turnover
138.37M
Amplitude
3.06%
52-week range
61.23 - 134.00

Valuation

P/E
35.68
P/E (TTM)
22.84
P/B
-188.35
EPS
2.56
Net profit
291.87M
Net assets
-55.29M

Share structure

Market cap
10.41B
Float cap
10.30B
Shares out
114.01M
Float shares
112.71M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 41% of range
61.23 134.00

31.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.96M net over the window

Short interest

Shares short
13.65M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Halozyme Therapeutics (HALO)?

Halozyme Therapeutics last traded at 91.35. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Halozyme Therapeutics's market cap?

About 10.41B.

What is the P/E ratio of Halozyme Therapeutics?

The trailing twelve-month P/E is 22.84, above its own 5-year average of 21.01 — toward the top of its historical range (79.28% percentile). See the Valuation tab for the full history.

Does Halozyme Therapeutics pay a dividend?

Halozyme Therapeutics does not currently pay a regular dividend.

Is Halozyme Therapeutics a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 129.75, which implies 42.0% upside from the current price. This is not investment advice.

What is Halozyme Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Halozyme Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Halozyme Therapeutics discussion 0 comments

Add a comment